logo-loader
viewPolarean Imaging PLC

Polarean completes patient enrolment for Phase III clinical trial of MRI lung scan technology

The company is aiming to show in the trials that its drug-device combination, which uses a type of Xenon gas in MRI machines, is as good as current methods for diagnosing breathing problems

Polarean Imaging PLC - Polarean completes patient enrolment for Phase III clinical trial of MRI lung scan technology
Polarean has enrolled 80 patients in the latest trial

Polarean Imaging PLC (LON:POLX) has completed patient enrolment for a Phase III clinical trial of its MRI lung scan technology.

The medical imaging specialist said it had enrolled 80 patients, 48 of which are in a lung transplant pathway while the remaining 32 are for lung resection, a process where part of the lung tissue is removed.

READ: Amphion no longer holds any shares in Polarean Imaging

Polarean is aiming to show in the trials that its drug-device combination, which uses a type of Xenon gas in a magnetic resonance imaging (MRI) machine, is as good as current methods for diagnosing breathing problems.

The trials are now in the image and statistical analysis stage, a process that is expected to take around 10 weeks and will conclude with a readout of the trial.

The readout will then form the basis for a pre-new drug application (NDA) meeting with the US Food and Drug Administration (FDA), with a formal application to be lodged in the second quarter of next year.

Polarean added that it had appointed Alex Dusek as its vice-president of commercialisation with immediate effect, consistent with its target of achieving commercial sales following FDA approval.

"The Company is pleased to have successfully completed enrolment for its Clinical Trials and looks forward to the next stage of statistical analysis ahead of readout and the proposed submission of the NDA”, said Polarean chief executive, Richard Hullihen.

“We are also pleased to welcome Alex Dusek to our team, as he brings a wealth of direct pharmaceutical industry launch preparation and commercialisation experience to Polarean, as we ramp up our commercialisation planning", he added.

In early trading on Thursday, Polarean’s shares were 0.7% lower at 22.9p.

Quick facts: Polarean Imaging PLC

Price: 35.55555 GBX

AIM:POLX
Market: AIM
Market Cap: £57.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Polarean Imaging in commercial launch mode for its lung function scanner

Polarean Imaging PLC's (LON:POLX) Richard Hullihen caught up with Proactive London's Andrew Scott following a recent pre-NDA meeting with the FDA. He says they're targeting the third quarter of this year to submit an NDA for its drug-device combination which uses hyperpolarised 129-Xenon gas...

on 19/6/20

2 min read